Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Viridian Therapeutics (VRDN)

Viridian Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VRDN
DateTimeSourceHeadlineSymbolCompany
07/02/202323:56Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
07/02/202323:46Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:VRDNViridian Therapeutics Inc
07/02/202323:35Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:VRDNViridian Therapeutics Inc
07/02/202313:00GlobeNewswire Inc.Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma ConferenceNASDAQ:VRDNViridian Therapeutics Inc
06/02/202312:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VRDNViridian Therapeutics Inc
06/02/202312:00GlobeNewswire Inc.Viridian Appoints Scott Myers as President and Chief Executive OfficerNASDAQ:VRDNViridian Therapeutics Inc
03/02/202323:13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
02/02/202321:05GlobeNewswire Inc.Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:VRDNViridian Therapeutics Inc
26/01/202322:03Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:VRDNViridian Therapeutics Inc
25/01/202323:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
18/01/202322:59Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
08/01/202313:00GlobeNewswire Inc.Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)NASDAQ:VRDNViridian Therapeutics Inc
05/01/202321:05GlobeNewswire Inc.Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
03/01/202313:00GlobeNewswire Inc.Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:VRDNViridian Therapeutics Inc
22/12/202221:43Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
21/12/202212:00GlobeNewswire Inc.Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye DiseaseNASDAQ:VRDNViridian Therapeutics Inc
07/12/202221:05GlobeNewswire Inc.Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
05/12/202223:29TipRanksLooking for Red-Hot Takeover Candidates? Here Are 2 Stocks on Analysts’ RadarNASDAQ:VRDNViridian Therapeutics Inc
05/12/202222:35TipRanksViridian Therapeutics (VRDN) Gets a Buy from OppenheimerNASDAQ:VRDNViridian Therapeutics Inc
02/12/202203:05TipRanksSVB Securities Sticks to Their Buy Rating for Viridian Therapeutics (VRDN)NASDAQ:VRDNViridian Therapeutics Inc
28/11/202212:00GlobeNewswire Inc.Viridian Therapeutics To Participate In The Evercore ISI HealthCONx ConferenceNASDAQ:VRDNViridian Therapeutics Inc
16/11/202223:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
16/11/202207:55TipRanksViridian Therapeutics (VRDN) Gets a Buy from SVB SecuritiesNASDAQ:VRDNViridian Therapeutics Inc
15/11/202211:50TipRanksAnalysts Are Bullish on Top Healthcare Stocks: Galectin Therapeutics (GALT), Viridian Therapeutics (VRDN)NASDAQ:VRDNViridian Therapeutics Inc
14/11/202223:05TipRanksJMP Securities Remains a Buy on Viridian Therapeutics (VRDN)NASDAQ:VRDNViridian Therapeutics Inc
14/11/202217:55TipRanksWedbush Remains a Buy on Viridian Therapeutics (VRDN)NASDAQ:VRDNViridian Therapeutics Inc
14/11/202212:10Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:VRDNViridian Therapeutics Inc
14/11/202212:01GlobeNewswire Inc.Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdatesNASDAQ:VRDNViridian Therapeutics Inc
14/11/202211:59GlobeNewswire Inc.Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)NASDAQ:VRDNViridian Therapeutics Inc
08/11/202212:05GlobeNewswire Inc.Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15thNASDAQ:VRDNViridian Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VRDN